"The Tulane Cancer Center is located in Downtown New Orleans and accredited by the Commission on Cancer. The center is home to expert oncology physicians specializing in all areas of cancer care."

During the past decade, Tulane Cancer Center conducted 22 clinical trials. In the 10-year time frame, 22 clinical trials started and 10 clinical trials were completed, i.e. on average, 45.5% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 8 clinical trials were completed. i.e. 57.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tulane Cancer Center" #1 sponsor was "Radiation Therapy Oncology Group" with 4 trials, followed by "SWOG Cancer Research Network" with 4 trials sponsored, "Endocyte" with 2 trials sponsored, "Merck Sharp & Dohme LLC" with 2 trials sponsored and "Tulane University" with 2 trials sponsored. Other sponsors include 19 different institutions and companies that sponsored additional 28 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tulane Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 11 trials as a collaborator, "Cancer and Leukemia Group B" with 2 trials as a collaborator, "NRG Oncology" with 2 trials as a collaborator, "North Central Cancer Treatment Group" with 2 trials as a collaborator and "SWOG Cancer Research Network" with 2 trials as a collaborator. Other collaborators include 8 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "Tulane Cancer Center" are "Prostate Cancer" (7 trials), "Head and Neck Cancer" (3 trials), "Prostatic Neoplasms" (3 trials), "Leukemia" (2 trials) and "Lung Cancer" (2 trials). Many other conditions were trialed in "Tulane Cancer Center" in a lesser frequency.

Most popular intervention types in "Tulane Cancer Center" are "Drug" (35 trials), "Biological" (6 trials), "Radiation" (6 trials), "Device" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "cisplatin" (4 trials), "radiation therapy" (4 trials), "177Lu-PSMA-617" (3 trials), "Placebo" (3 trials) and "cytarabine" (3 trials). Other intervention names were less common.

The vast majority of trials in "Tulane Cancer Center" are 25 trials for "All" genders, 12 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Tulane Cancer Center". undefined are not yet recruiting, 8 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Tulane Cancer Center, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Tulane Cancer Center, 6 "Phase 1" clinical trials were conducted, 18 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".